OncLive SOSS

Authors

Faisal Musa, MD

Latest:

Do We Still Need Physical Exams in the Era of Advanced Imaging Technologies?

Throughout fellowship, my experiences working with patients in clinic have taught me many lessons.

Faith Davies, MD, MBBCh, MRCP, FRCPath, University of Arkansas for Medical Sciences

Faith E. Davies, MD, NYU Langone's Perlmutter Cancer Center

Latest:

Dr Davies on Addressing Global Gaps in Multiple Myeloma Care

Faith E. Davies, MD, discusses strategies for rectifying global gaps and addressing unmet needs in multiple myeloma care.

Farah Succaria, MD

Latest:

Dr. Succaria on Targetable Immune Checkpoints in Head and Neck Cancer

Farah Succaria, MD, postdoctoral fellow, Johns Hopkins Medicine, discusses targetable immune checkpoints in head and neck squamous cell carcinoma.

Latest:

Wellsphere Blogger Flap Raises Questions about Content Ownership

It started with an e-mail to thousands of health bloggers from Dr. Geoff Rutledge, Chief Medical Information Officer at the health website Wellsphere.

Farhad Kosari, PhD

Latest:

Dr. Kosari on Antitumor Immunity in Small Cell Lung Cancer

Farhad Kosari, PhD, assistant professor of Biochemistry and Molecular Biology, discusses anti-tumor immunity as a key determinant for small-cell lung cancer (SCLC) survivorship.

Farhad Ravandi-Kashani, MD

Latest:

Dr Ravandi-Kashani on the FDA Approval of Luspatercept in MDS

Farhad Ravandi-Kashani, MD, discusses the FDA approval of luspatercept in myelodysplastic syndrome.

Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center

Latest:

Updates in the Management of Hairy Cell Leukemia

Farhad Ravandi, MBBS

Latest:

Dr. Ravandi on BiTE Antibody AMG 330 Data in Relapsed/Refractory AML

Farhad Ravandi, MBBS, professor of medicine, department of leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase I first-in-human study of AMG 330, an anti-CD33 bispecific T-Cell engager (BiTE) antibody construct, in patients with relapsed/refractory acute myeloid leukemia (AML) during the 2018 ASH Annual Meeting.

Farhad Ravandi, MD

Latest:

Dr. Farhad Ravandi Discusses Vosaroxin in the VALOR Trial

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center in Houston, describes results from the phase III VALOR trial that explored vosaroxin plus cytarabine versus placebo and cytarabine in patients with first relapsed or refractory acute myeloid leukemia.

Farrukh Awan, MBBS

Latest:

Dr Awan on Treatment Considerations With Pirtobrutinib in Hematologic Malignancies

Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.

Farrukh Awan, MD

Farrukh Awan, MD, is a professor in the Department of Internal Medicine and member of the Division of Hematology and Oncology at Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center.

Latest:

Dr Awan on Patient Characteristics Associated With CAR T-Cell Candidacy in CLL

Farrukh Awan, MD, discusses patient characteristics that confer candidacy for CAR T-cell therapy for the management of chronic lymphocytic leukemia.

Farrukh Awan, MD, University of Texas Southwestern Medical Center

Farshid Dayyani, MD, University of California Irvine School of Medicine

Farzana Sayani, MD, University of Pennsylvania

Fatima Cardoso, MD

Latest:

Dr Cardoso on Outcomes With Elinzanetant for Hot Flashes in HR+ Breast Cancer

Fatima Cardoso, MD, MSc, FESMO, discusses quality-of-life outcomes with elinzanetant for the management of hot flashes in hormone receptor–positive breast cancer.

Fausto Roila, MD

Latest:

Dr. Roila on Aprepitant for the Prevention of Cisplatin-Induced Delayed Emesis

Fausto Roila, MD, chair, Medical Oncology Division, S. Maria Hospital, Terni, Italy, discusses an analysis of aprepitant for the prevention of cisplatin-induced delayed emesis.

Federico Aucejo, MD

Latest:

First Liver Transplant Surgery Performed in Patient With CRC Metastases

Although the standard-of-care treatment for patients with liver metastases developing from colorectal cancer is liver resection, only one-third of these patients are candidates for surgery.

Federico Ustaris, MD

Latest:

Effective Management and Prevention of Neratinib-Induced Diarrhea

Safety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.

Felix M. Chinea, MD

Latest:

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.